Jnana Therapeutics

BOSTON, MA · Founded 2016 · CIK 0001879148 · Biotech · Acquired

Chemoproteomics platform for small molecule drug discovery

jnanatx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$110M
2 Form D · Nov 2022
47 months since last filing
Contracts
—
No federal contracts on record
Patents
24
2 granted · 22 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$50,000,000
Private capital raisedForm D · SEC$59,999,998
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1731Design Therapeutics, Inc.—$171M
1732Halia Therapeutics, Inc.—$27M
1733Iterum Therapeutics plc—$127M
1734Jnana Therapeutics—$110M
1735STRYKAGEN CORPORATION——
1736MB RESEARCH LABORATORIES, INC.——
1737EpimedX, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 14 related persons
  • Joel BarrishExecutive Officer
  • Caroline BeerExecutive Officer
  • Brian CaliDirector
  • Annie ChenDirector
  • Matthew HammondDirector
  • Kevin KinsellaDirector
  • Joanne KotzDirector · Executive Officer
  • Terrance McGuireDirector
  • Donald NicholsonDirector
  • Douglas PaganExecutive Officer
  • Ronald Renaud, Jr.Director
  • Carlo RizzutoDirector
  • Stuart SchreiberDirector
  • George VratsanosExecutive Officer

Patents

USPTO · 2 granted of 24
  • Treating Pku With Spiro-substituted And Other Piperidine Inhibitors Of SLC6A19 Functionapplication
  • Small Molecule Inhibitors Of Mammalian SLC6A19 Functiongranted
  • Dosing Regimen For Treating Pku With A Piperidine Inhibitor Of SLC6A19 Functionapplication
  • Small Molecule Inhibitors Of Mammalian SLC6A19 Functionapplication
  • Small Molecule Inhibitors Of Mammalian SLC6A19 Functionapplication
  • Small Molecule Inhibitors Of Mammalian SLC6A19 Functionapplication
  • Small Molecule Inhibitors Of Mammalian SLC6A19 Functiongranted
  • Small Molecule Inhibitors Of Mammalian SLC6A19 Functionapplication
  • Treating Chronic Kidney Disease With A Combination Of A SLC6A19 Inhibitor And A GLP-1 Agonistapplication
  • Treating Chronic Kidney Disease With A Combination Of SLC6A19 And SGLT2 Inhibitorsapplication
  • Bicyclic Heteroaryl-containing Piperidine Inhibitors Of SLC6A19 Functionapplication
  • Crystalline Forms Of A Piperidine Inhibitor Of SLC6A19 Functionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.